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Meeting ReportSUMMARYCross-linking mass spectrometry (MS) has substantially matured as a method over the past 2 decades
through parallel development in multiple labs, demonstrating its applicability to protein structure determina-
tion, conformation analysis, and mapping protein interactions in complex mixtures. Cross-linking MS has
become amuch-appreciated and routinely applied tool, especially in structural biology. Therefore, it is timely
that the community commits to the development of methodological and reporting standards. This white pa-
per builds on an open process comprising a number of events at community conferences since 2015 and
identifies aspects of Cross-linking MS for which guidelines should be developed as part of a Cross-linking
MS standards initiative.INTRODUCTION
Cross-linking for structural analysis goes back at least as far as
1958, when the topology of insulin was investigated with the help
of a cross-linking reagent (Zahn and Meienhofer, 1958). Intro-
ducing mass spectrometry (MS) for the detection of cross-links
(cross-linking mass spectrometry, here abbreviated as Cross-
linking MS, but also known as XL-MS, CXMS, or CLMS) led to
increased accuracy of identifying which pairs of proteins were
linked together in heteromeric complexes and increased resolu-
tion by revealing the identity of the linked residues and, thus, the
interaction regions within these proteins. Technical progress,
including the wide variety of parallel developments, and biolog-
ical applications have been reviewed extensively in recent years
(Leitner et al., 2016; O’Reilly and Rappsilber, 2018; Sinz, 2018;
Steigenberger et al., 2020; Yu and Huang, 2018).
Encouraged by the Worldwide Protein Data Bank (wwPDB)
Task Force for Integrative/Hybrid Methods (Berman et al.,
2019; Sali et al., 2015) to provide experimentalists and modelers
with a stable access point to cross-linking data, an initial open
gathering on standards in the Cross-linking MS field took place
at the 14th Human Proteome Organization (HUPO) World
Congress 2015 in Vancouver (Canada). This effort was carried
forward into an open podium discussion at the 5th Symposium
on Structural Proteomics in Halle/Saale (Germany) later that
year. At the HUPO-Proteomics Standards Initiative (PSI) meeting
2016 in Ghent (Belgium), an agreement was reached to support
cross-linking data starting from v.1.2 of mzIdentML, the prote-
omics data standard for peptide/protein identification informa-
tion (Vizcaı́no et al., 2017). Following a closed meeting of senior
investigators at the 7th Symposium on Structural Proteomics in
Vienna (Austria), 2017, again an open podium discussion took
place at the 8th Symposium on Structural Proteomics in Berlin
(Germany), 2018. A first community-wide, comparative Cross-
linking MS study was published in 2019 (Iacobucci et al.,
2019), organized through the European Union COST Action
BM1403 as an initiative to develop activities in structural prote-
omics at large, including Cross-linking MS. Discussions were
continued during three meetings in 2019: the American Society
for Mass Spectrometry Sanibel Conference 2019 entitled
‘‘Chemical Cross-linking and Covalent Labeling: From Proteins
to Cellular Networks,’’ the Dagstuhl Seminar 19351 ‘‘Computa-
tional Proteomics,’’ and the 18th HUPO World Congress 2019
in Adelaide. These efforts were brought together at the 9th Sym-
posium on Structural Proteomics in Göttingen (Germany) later
that year. A questionnaire on the standardization of Cross-linking
MSwas circulated among the participants of themeeting. Also, a1260 Structure 28, November 3, 2020discussion group consisting of 20 research labs and companies
with strong interests in Cross-linking MS, and thus a strong rep-
resentation of the field, formulated challenges and recommen-
dations for the field. These were publicly discussed within the
conference at the end of the meeting. The resulting draft docu-
ment was then circulated to participants and additional labs in
Cross-linking MS that were not represented in Göttingen to pro-
vide them with an opportunity to participate. Following the dis-
cussions at these meetings, this white paper is now supported
by about 30 academic laboratories and companies engaged in
developing, applying, and supporting Cross-linking MS, there-
fore representing a substantial fraction of the field.
CROSS-LINKING AT THE INTERFACE OF PROTEOMICS
AND STRUCTURAL BIOLOGY
The definition of Cross-linking MS is as follows: non-covalent in-
teractions or proximities within or between biomolecules are
covalently fixed for their detection in an otherwise dissociative
analytical process involving a mass spectrometer.
Cross-linking MS shares some similarities with conventional
structural biology techniques, but also has some distinct fea-
tures. For example, structural dynamics in solution is not appro-
priately reflected in static structures obtained by X-ray crystal-
lography. NMR spectroscopy and, to some extent, (cryo-)
electron microscopy (EM) are able to reveal ensembles of
conformational states. Cross-linking data also reflect such solu-
tion-phase dynamics and are often able to provide crucial con-
tact information about flexible regions in proteins that remain
inaccessible to EM or crystallography and are therefore absent
in many deposited structures and models. Due to this comple-
mentarity to established structural methods, Cross-linking MS
has gained acceptance in the structural biology community,
and efforts toward standardization should also align with best
practices in that field.
Cross-linkingMS is most intimately connected to a wide range
of applications in structural biology, but is at the same time
rooted in MS-based proteomics, two fields where substantial ef-
forts in standardization and harmonization have developed in the
past decades (Berman et al., 2006; Burley et al., 2017; Deutsch
et al., 2017; Lawson et al., 2011; Montelione et al., 2013; Sali
et al., 2015; Schwede et al., 2009; Trewhella et al., 2013, 2017;
Vallat et al., 2018). However, the primary data output from
Cross-linking MS experiments already differs substantially
from conventional protein identification and quantification work-
flows in proteomics. Instead of identifying single peptide chains
that then jointly identify proteins, the main types of identification
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Figure 1. General Cross-linking MS Workflow
(A) Cross-linkers comprise various chemistries and spacer lengths. Depending on the experimental workflow used, the cross-linker spacer may be cleavable in
the mass spectrometer (C) or isotope labeled (star) or have moieties that can be biochemically enriched (E) and chemically released (R).
(B) Concentrations and reaction times must be empirically tested for each application to achieve optimal amounts of cross-linking.
(C) Proteins can be digested in solution or in gel to produce a mixture of cross-linked and linear peptides. Also ‘‘dead-end’’ products, where the cross-linker has
hydrolyzed on one end; ‘‘loop-links,’’ where the cross-link ends up in a single peptide; and higher-order products, comprising more than two peptides and/or
more than one cross-linker moiety, can form.
(D) After digestion, cross-linked peptides are often enriched through chromatographic methods, such as size-exclusion chromatography, strong-cation ex-
change chromatography, or affinity chromatography.
(E) MS/MS acquisition pipelines have been designed to increase the likelihood of selecting cross-linked peptide precursors for fragmentation.
(F) Various search software solutions have been developed to identify the two linked peptides from the spectra.
(G) Through methods that determine the false discovery rate (FDR), the list of matches is cut to the desired confidence.
(H and I) The links are visualized and/or (I) used as part of integrative modeling.
(J) The data are deposited in public repositories. In part adapted from O’Reilly and Rappsilber, 2018.
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Meeting Reportin Cross-linkingMS are pairs of covalently connected, i.e., cross-
linked, peptides, which may originate from the same or two
different proteins. These are then combined into sets of cross-
linking sites (pairs of cross-linked residues) or, for samples of
higher complexity, pairs of interacting proteins. Cross-linking in-
volves the use of one or more of a large variety of cross-linking
reagents, data acquisition strategies, and data analysis ap-
proaches. Inevitably, this diversity will pose particular challenges
when it comes to standardizing workflows and data formats and
introducing reporting guidelines for the community to adhere to.Any initiative that attempts to establish standards and guide-
lines in relation to cross-linking needs to include most of today’s
diverse cross-linking community.We are in the fortunate position
to witness the growth of this community and one might broadly
define members of the cross-linking community as (1) re-
searchers or labs that develop cross-linking chemistries, work-
flows, software, etc., and (2) those that apply cross-linking to
address questions in structural biology, molecular biology, sys-
tems biology, and so on. In some cases, the focus of research
groups in the Cross-linking MS field may, of course, coverStructure 28, November 3, 2020 1261
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Meeting Reportboth directions. In addition, cross-linking methods are not
restricted to the study of protein-protein interactions and protein
conformations, but may also include interactions with other clas-
ses of biomolecules, including other biopolymers and small mol-
ecules. In fact, natural processes can lead to cross-links, and
these products can be analyzed by the tools of Cross-linkingMS.
To increase transparency and access to results, the cross-
linking community has already established some organizational
liaisons, includingmost prominently with proteomics data repos-
itories (ProteomeXchange Consortium [PXC] partners [Deutsch
et al., 2020], in particular PRIDE [Perez-Riverol et al., 2019] and
jPOST [Moriya et al., 2019]) and repositories for integrative/
hybrid structural biology (particularly PDB-Dev, a prototype re-
pository of the wwPDB for integrative structures [Burley et al.,
2017; Vallat et al., 2018]). At the moment, these two types of re-
positories cover different parts of the cross-linking workflow and
are not yet interconnected. In the following, we will outline the
different steps of this workflow and how researchers from
different communities may benefit from increased reliability,
transparency, and access.
THE CROSS-LINKING EXPERIMENT: FROM SAMPLE TO
SHARED DATA
Figure 1 outlines the different steps of a cross-linking experiment
and highlights specific steps of the procedure. For the sake of
this discussion, we will assume that, independent of the sample
type and the specific chemistry involved, a protein or protein
mixture has been cross-linked and subsequently digested into
peptides using one or more proteases, and the resulting peptide
mixture has been analyzed by liquid chromatography coupled to
tandem MS (LC-MS/MS). This experimental workflow can
deliver (1) sites of cross-links that may inform modeling of a pro-
tein or protein complex structure and (2) information on which
proteins were linked and thus interacting in a possibly highly
complex biological mixture. The raw/primary data emerging
from an LC-MS/MS experiment are considered the starting point
of the data analysis pipeline. Primary data that are generated in
vendor-specific formats may first be converted into open file for-
mats suitable for database searching (although some programs
may be able to workwith vendor-specific formats directly). Either
way, a peak list is generated that corresponds to the experimen-
tally acquired MS/MS spectra that are searched against a pro-
tein sequence database of interest. This database may contain
anything from a few protein sequences of interest up to a whole
proteome database.
Successful matches to the experimental spectra are desig-
nated either peptide-spectrum matches (PSMs) or cross-link-
spectrum matches (CSM, XSM). These matches correspond to
the (putative) assignment of the sequence of two peptides con-
nected by a cross-link at defined positions within the peptide se-
quences. This has implications on error handling, as will be dis-
cussed below. Therefore, the term cross-link-spectrum match
might be more suitable. CSMs/XSMs may subsequently be
collapsed into higher-level contact information: peptide pairs,
residue pairs, or protein pairs. It should be noted that Cross-link-
ing MS also has to address the protein inference problem of pro-
teomics (Nesvizhskii and Aebersold, 2005; Rappsilber and
Mann, 2002) due to the existence of multiple proteins with over-1262 Structure 28, November 3, 2020lapping sequences. In addition, as multiple copies of the same
protein are present in a sample, cross-links of a protein to itself
may be intramolecular or intermolecular. Often one cannot
distinguish these self-links without dedicated experimental
design or additional considerations (Lima et al., 2018; Taverner
et al., 2002).
Identifications at all levels are associated with some error rate.
This concerns the identity of the peptides (characterized by the
false discovery rate, FDR) and the localization of the cross-link-
ing sites (characterized by the false localization rate, FLR). FDRs
can, in principle, be determined by so-called target/decoy
search strategies whereby the MS/MS spectra are searched
against the target sequence database and a database of non-
natural decoy sequences that are typically obtained by reversing
or shuffling the sequences contained in the target database
(Fischer and Rappsilber, 2017, 2018; Maiolica et al., 2007; Walz-
thoeni et al., 2012). The frequency of matches to the decoy data-
base is then assumed to be equivalent to the frequency of
random hits to the target database; this correlation is used to
calculate the FDR. There are several caveats to consider for
FDR control in cross-linking: first, the mere fact that a combina-
tion of two peptides is identified raises the chance for error
compared with single peptide chain identifications. It that suf-
fices that if one of the two peptides is false, then the whole
assignment will be false (Trnka et al., 2014). Also, false positives
increase proportionally when moving from the CSM/XSM to the
peptide pair to the protein pair level (Fischer and Rappsilber,
2017). This error propagation is a result of the typically observed
redundancy of true positive hits (multiple CSMs/XSMs per pep-
tide pair, multiple peptide pairs per protein pair), while random
false positives by definition are less redundant. Therefore,
FDRs need to be controlled at multiple levels, in the same way
as for conventional proteomics experiments, when moving
from CSMs/XSMs to identified peptides and identified proteins.
Second, the search spaces of self and heteromeric cross-links
are of different sizes. Therefore, the error of self and heteromeric
links must be considered separately (Lenz et al., 2020; Walz-
thoeni et al., 2012). Third, for samples of limited complexity,
when using only a small sequence database, and dependent
on the cross-linking chemistry and data analysis strategy, there
may be an insufficient number of decoy hits for an accurate
determination of FDRs. Most FDR strategies try to model the
tail of the false positive score distributions, but in a sparse data-
set this boundary is strongly affected by the selection of search
parameters such as database composition (inclusion/exclusion
of contaminant proteins) or the defined specificity of the cross-
linking reagent.
Although the field has already seen substantial progress in
FDR control, many commonly used software tools do not yet
support FDR control at all levels, and there is no consensus for
how FDRs should be collected for the various experimental de-
signs currently applied in cross-linking (Beveridge et al., 2020;
Keller et al., 2019a; Yugandhar et al., 2020). When dealing with
error rates at the cross-linking site level, the FLR (related to the
confidence of correctly assigning the cross-linked residues
within the two peptide sequences) also needs to be considered.
This is an even more challenging problem because the precise
localization of the cross-link sites requires the observation of
not just any fragments of the peptides but those that allow the
ll
Meeting Reportexclusion of alternative sites. Often, the linkage site is assigned
based on the known or assumed reactivity of the cross-linker,
an approach that fails at least when using photo-cross-linking
(Schneider et al., 2018). It is worthwhile to note that cross-
links reveal proximity, and it remains to be seen what precision
level is required by modeling. Here, Cross-linking MS may
differ from post-translational modification (PTM) mapping, for
example, where the exact PTM site can be critical for mecha-
nistic studies. Additional challenges arise when pairs of the
same peptides, but linked at different sites, co-elute chromato-
graphically.
Eventually, the outcomes of cross-linking experiments are
made publicly available through different channels, typically
journals and data repositories. Research articles provide exper-
imental details and mostly qualitative, but increasingly also
quantitative, cross-linking results (Chen and Rappsilber, 2018),
in widely varying degrees of detail. Cross-linking identifications
are typically reported in a tabular format in the main article or
(more commonly) integrated into the online supporting informa-
tion section as stand-alone tables or formatted in a joint file with
other supplementary data, for example, in PDF format. Although
this solution may at least fulfill minimum expectations of data
transparency, such a deposition complicates data reuse and re-
analysis, especially as the formatting lacks a common standard
specifying what essential data should be included. Proteomics
data repositories already offer some support for cross-linking
datasets; for example, a project can be designated as a cross-
linking study in the ProteomeXchange partner repository PRIDE,
and all data necessary for a ‘‘complete’’ submission can be pro-
vided. However, at the time of writing, the submission is labeled
as ‘‘partial’’ and therefore may give the false impression of not
entirely adhering to open-data-sharing principles and cannot
be cited through a digital object identifier, which is increasingly
becoming part of open data policies (Gierasch et al., 2020).
The PXC partner repository jPOST accepts such submissions
as ‘‘complete,’’ fortunately. Version 1.2 of the open mzIdentML
standard (Vizcaı́no et al., 2017), developed by the HUPO-PSI
and the official PSI validator, offers support for some cross-link-
ing results (Montecchi-Palazzi et al., 2009), but not all workflows
are supported; for example, the increasingly popular cleavable
cross-linking reagents are not completely covered. The less
complex, tab-delimited mzTab file format would be an alter-
native.
Apart from the MS-centric data deposition, integrating cross-
linking data into other resources, such as protein sequence da-
tabases (e.g., UniProt; UniProt Consortium, 2019) or protein
interaction databases such as IntAct (Orchard et al., 2014),
STRING (Szklarczyk et al., 2019), BioGRID (Oughtred et al.,
2019), or Complex Portal (Meldal et al., 2019), would be benefi-
cial. In fact, IntAct is already including published cross-linking
data on protein-protein interactions, even though the Cross-link-
ing MS field has not established appropriate quality control
mechanisms. Some cross-linking data are also available through
individual lab efforts such as XLinkDB (Keller et al., 2019b). In the
specific context of the use of cross-linking data for integrative/
hybrid modeling, the data dictionary (Vallat et al., 2018) used
by PDB-Dev offers support for cross-linking site-centric distance
restraints. However, there is no interoperability between these
resources that would seamlessly connect all these different re-positories and databases. The following section will explain
why this would be highly valuable to different audiences.
REQUIREMENTS FOR MAXIMAL IMPACT OF
CROSS-LINKING MS
To maximize the use of Cross-linking MS, its data should be
made available adhering to the principles of FAIR (findable,
accessible, interoperable, reusable) (Wilkinson et al., 2016). In
addition, all of the experimental steps should be transparent to
others by providing a sufficient amount of information, defined
jointly by the community, and by providing this information in a
suitable format in articles and in data repositories. This has
been done for multiple other proteomics data types (http://
www.psidev.info/miape) (Taylor et al., 2007). However, the
different communities that stand to benefit from Cross-linking
MS data require different types of data and levels of detail for
reuse, and this needs to be considered before planning a course
of action.
Peers (wet- and dry-lab scientists working in the cross-linking
area)may use data to learn about new developments in the field,
to assess the validity of published work, and to reanalyze exist-
ing datasets, for example, in the context of software develop-
ment. For these purposes, detailed information and access to
many different files are required. This includes raw/primary MS
data and peak lists used for the initial search together with the
search configuration and database. It also includes ‘‘technical’’
metadata (including details related to the original search such
as software [version] and search parameters) and details about
the instrumentation for which a first example of a reporting tem-
plate already exists (Iacobucci et al., 2019). Finally, one also re-
quires identifications at different levels (CSMs/XSMs, peptide
pairs, residue/site pairs, protein pairs), including decoys, details
about the FDR control (what approach was used and at which
levels FDR control was applied, although this should ideally be
standardized), and ‘‘biological’’ metadata (related to the nature
of the sample and the experimental design, e.g., replicates or
perturbations and sample treatment), together with the link to a
publication if applicable.
Structural, computational, or systems biologists are more likely
not to work with the raw MS data themselves, but they will rather
be interested in using the outcomes of cross-linking experiments
formodeling protein conformations, protein complexes, or cellular
networks. Consequently, these communities may primarily be
interested in the identifications at the residue level or protein-pro-
tein interaction level with associated measures of confidence
(FDR) and, optionally, abundance. The chemistry of the cross-link-
ing reagent should be well defined regarding reactive sites and
spacer length to define appropriate boundaries for cross-link re-
straints. A stable link to the primary data is required, for example,
in a proteomics repository, and the data need to be provided in
standardized form (also a wwPDB Integrative/Hybrid Methods
Task Force recommendation; Berman et al., 2019; Sali et al.,
2015). The data should be findable and experimental details docu-
mented, i.e., some basic technical and biological metadata need
to be associated with the data together with a link to a more
detailed description, ideally a publication.
Finally, molecular and cell biologists and other researchers
interested in protein interactions in general might be interestedStructure 28, November 3, 2020 1263
Table 1. Recommendations (Single-Sentence Summaries of the Field’s To-Do List)
No. Recommendation
1 Define best practices in experimental design for different applications of Cross-linking MS.
2 Find consensus on procedures to reliably assess error rates for all workflow types and at different levels (site pair to protein pair).
3 Ensure support by and complete integration with proteomics data repositories such as those included in ProteomeXchange.
4 Develop consistent terminology and common vocabularies for metadata annotation of Cross-linking MS datasets.
5 Provide enhanced support for data sharing with community-agreed-upon file formats such as mzIdentML or mzTab.
6 Define minimal requirements for reporting Cross-linking MS data in peer-reviewed publications.
7 Facilitate access to modelers by providing results in formats suitable for structure and model repositories, such as PDB/PDB-Dev.
8 Develop parsers for data integration in interaction databases and develop easily accessible visualization tools.
9 Ensure flexibility for new developments in the field; not all steps need to be standardized as workflows evolve.
10 Organize benchmarking studies for objective comparisons of key experimental and computational steps.
11 Establish minimum reporting standards for reporting new or improved reagents and software tools.
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between proteins and/or specific residues in proteins. For these
communities, the biggest value will come from access through
an intuitive interface to identifications at the residue level or pro-
tein-protein interaction level with associated measures of confi-
dence (FDR). This might be best achieved by the integration of
such data into resources (databases) that they normally use,
such as IntAct, STRING, or UniProt. A useful point of reference
would be the HUPOPSI-MI standard, which recordsmolecular in-
teractions without including the supporting MS data. Either these
access points may need to expand their data visualization to
include topological information or an additional interface may be
needed that provides intuitive access also to residue-level infor-
mation, akin to what is offered by tools such as xVis, xiNET, and
xiVIEW (Combe et al., 2015; Graham et al., 2019; Grimm et al.,
2015), or in field databases such as ProXL (Riffle et al., 2016).
In summary, different user bases require a different scope and
granularity of the information that is obtained from cross-linking
experiments. In any case, the ideal scenario would be a trans-
parent and seamless flow of information to and from all re-
sources connected to cross-linking in standardized formats,
raising the question of which parts of the workflow can and
should be standardized.
RECOMMENDATIONS AS TO WHERE THE
CROSS-LINKING MS FIELD REQUIRES
STANDARDIZATION
We feel that the Cross-linking MS field will benefit the most from
field-developed standards in four specific areas of Cross-linking
MS analyses and reporting, leading to the 11 tasks summarized
in Table 1 and presented in detail below.
Workflows/Experiments
Recommendation 1: Best Practice in Experimental
Design
Although there is a large diversity of analytical tools and con-
cepts being utilized in Cross-linking MS, they are all based on
the same principle of preserving structural information by intro-
ducing artificial covalent bonds in and between biomolecules
that would otherwise be lost during themass spectrometric anal-
ysis. Therefore, guidelines should be developed to ensure that
the resulting data can conclusively be interpreted. This should1264 Structure 28, November 3, 2020address fundamental aspects of experimental design such as
the number and type of replicates and whether different recom-
mendations are required for different types of experiments, e.g.,
the analysis of highly purified, individual proteins or small protein
complexes versus whole-cell analysis and qualitative versus
quantitative experiments. This may include control experiments
to address oligomerization or sample integrity. An appropriate
mechanism has to be set up that allows for finding where best
practice guidelines are needed and developing these guidelines
while allowing their continuous adaptation as understanding of
Cross-linking MS expands.
Recommendation 2: Error Assessment
It is important to determine the error in Cross-linking MS data by
a transparent and thoroughly tested method. There are currently
a large number ofmethods for FDR control that are usually based
on the target-decoy approach. In addition, comparisons are
made to available high-resolution structures, which has its limita-
tions, as these are also experimental data and describe a static
representation of a protein or protein complex. It is of the utmost
importance that the field arrives at a consensus for procedures
that return a reliable error assessment. It is also important that
the limits of these procedures be mapped out. It is hoped that
future studies will employ this field-agreed-upon error assess-
mentmethod in its respective current form. This would be helped
by swift integration into themain data analysis workflows by their
respective developers. Changes in the procedure must be well
documented and thoroughly tested before being implemented.
Data Sharing
Recommendation 3: Public Repositories
All Cross-linkingMSdata should be shared in an open and stable
way in a public repository to provide an identifier such as an
accession number and a defined data structure to cross-refer-
ence cross-linking datasets in other resources. This repository
would require standardized metadata (Recommendation 4)
and standardized file formats (Recommendation 5). This is
already the case for proteomics data and would just require
Cross-linking MS specific adaptations of existing proteomics re-
positories. The PRIDE repository, as one of the PXC members,
has committed to being a partner in this endeavor. Basic func-
tionality for ‘‘partial’’ submissions (raw MS data and some meta-
data) is already available, but should be considered theminimum
baseline for data sharing. For a ‘‘complete’’ submission, some
ll
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MS results. Another PXC member, the jPOST repository, has
already accepted several Cross-linking MS projects with ‘‘com-
plete’’ submission, but will continually need to work with the field
to universally address the diverse data modalities of Cross-link-
ing MS. Ultimately, the criteria for ‘‘complete’’ submission are
Cross-linking MS specific and need to be defined by the field
to then be implemented through basic, and in the longer term
also more elaborate, checks during submission. Ideally, making
‘‘complete’’ submissions for Cross-linking MS data would be in-
dependent of criteria applied to the data of other fields.
The Cross-linking MS data that enter public repositories
should receive a quality check at all levels, preferably automati-
cally at the point of uploading. This pertains to the elemental
integrity of the files and their adherence to the agreed-upon stan-
dard formats, which includes semantic validation and readability
by parsers that increase the data availability and reach, consis-
tency tests, and other data quality metrics such as a measure
of confidence. For this, appropriate software will need to be
developed and maintained in a field effort, in collaboration with
data repositories. Results of Cross-linking MS that then enter
other repositories should do so together with a measure of con-
fidence (see Recommendation 8).
Recommendation 4: Metadata
All information needed to reproduce Cross-linking MS results
must be provided in full. Duplications in locations where this takes
place should be minimized, though. A minimal set of critical infor-
mation that is required for a basic understanding of theCross-link-
ing MS results should be provided as part of data submission. A
standardized description of a cross-linking experiment requires
the definition of common, controlled vocabularies. XLMOD
(Mayer, 2020) (https://raw.githubusercontent.com/HUPO-PSI/
mzIdentML/master/cv/XLMOD.obo) is an effort coordinated via
the HUPO-PSI on controlled vocabularies in cross-linking that
covers ‘‘cross-linking reagents, cross-linker related post-transla-
tional modifications, and derivatisation reagents for GC-MS and
LC-MS.’’ Other terms for a standardized, minimal description of
a Cross-linking MS experiment will need to be defined in addi-
tional efforts. Full experimental details should be provided in the
experimental section of publications. A good starting point of
what should be included here are the recommendations emerging
from a first community study (Iacobucci et al., 2019). This is
currently taking a tabular form as is also practiced in other fields
(Henderson et al., 2012; Masson et al., 2019; Montelione et al.,
2013; Read et al., 2011; Trewhella et al., 2017). Metadata about
instrumentation and data acquisition parameters would ideally
be parsed from the raw data before submission and written auto-
matically into the submitted file. Likewise, search parameters
should automatically be documented in a form so that users can
effortlessly pass them on to the data repository as part of their
submission. It would bedesirable tominimize the number of sepa-
rate files by combining all relevant experimental information
together with the results into a single file.
Recommendation 5: Community-Agreed-upon File
Formats
All data should be shared in an open and community-agreed-
upon format that is extensible to support the evolving needs of
the community. This has been successfully performed for peak
list formats such as mzML. A standard result file format shouldbe developed and include a complete list of target and decoy
identifications as potential true and known noise distributions.
Integrative/hybrid modeling is tolerant to substantial error rates,
and including the known noise (decoy matches) allows the
modeling field to build ways to deal with noise in cross-linking
data into their procedures (Berman et al., 2019; Rout and Sali,
2019). From amodeling perspective, such decoymatches repre-
sent an initial noise distribution that can be converted into amore
accurate noise model by FDR estimation procedures. This
format might be based on already existing standard formats
such as mzIdentML or mzTab, which are supported by the
HUPO-PSI as the initiative in the proteomics field on procedures
for standardization. mzIdentML 1.2 would be a starting point for
further efforts since it already supports some, albeit not all, types
of cross-linking data (Vizcaı́no et al., 2017). Cross-linking data
are currently not supported in mzTab, but mzTab could be
extended to accommodate these data. In addition to output for-
mats, one should also keep an eye on input files and their stan-
dardization, which includes mzML for peak lists (Martens et al.,
2011) and PEFF for sequence databases (Binz et al., 2019).
Part of integrating the needs of the cross-linking community
into general proteomics standards will be developing parser li-
braries, readers, and writers. Cross-linking MS search software
should be adapted to write results and search parameters in a
standards compliant form to allow direct sharing of data, meta-
data, and results. As cross-linking is evolving as a method, this
will also lead to evolving standards and a continuous need to up-
date software tools. We acknowledge that the complexity of the
data makes the whole process of changing existing software
tools and maintaining them challenging.
Recommendation 6: Publication Guidelines
Publication guidelines should be developed for what constitutes
a sufficiently detailed description of experimental design
(Recommendation 1), sample and data processing (Recommen-
dations 2 and 4), and presentation of results (Recommendations
3 and 5).
Knowledge Transfer
Recommendation 7: Access to Cross-linking MS Results
for Modeling
Efforts should be undertaken to maximize access of other re-
searchers and communities to the link and interaction data ob-
tained by Cross-linking MS. In fact, wwPDB/PDB-Dev has
reached out in the name of the structural biology and modeling
field with the specific requirement of having access to Cross-
linking MS data held in a public repository in standardized form
and with quality descriptors. These requirements are going to
be met by Recommendations 2 (FDR), 3 (data repository), and
5 (file formats). Once Cross-linkingMS formats have been estab-
lished, parsers can and will be written to stably link the data into
the workflows of the modeling community and the prototype
archiving system for structural models, PDB-Dev.
Recommendation 8: Accessibility of Cross-linking MS
Data to Experimentalists
Providing biological researchers with efficient access to Cross-
linking MS results requires those data to be integrated into exist-
ing resources containing protein-protein interaction information,
such as IntAct, UniProt, and STRING. This requires, first of all,
Cross-linking MS data to make it into these repositories in anStructure 28, November 3, 2020 1265
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tion 2 and 3). This includes the writing of parsers that convert
Cross-linking MS results into formats for molecular interactions
and protein complexes. This also mandates the further develop-
ment of cross-linking data visualization tools and their integration
with public databases. These visualization tools can be broadly
categorized by their purpose: investigating spectral data, protein
structure, or protein interaction networks. This does not neces-
sarily comprise a definitive listing, as these tools and their inte-
gration with one another and other tools are under active devel-
opment. Even within the first category, consisting of spectral
interpretations, the often long lists of cross-linked proteins and
cross-linked amino acid residues returned by Cross-linking MS
are not intuitively understandable. The ability to display resi-
due-resolution information provided by Cross-linking MS has
been shown to provide a more suitable visual data interaction
platform (Combe et al., 2015; Graham et al., 2019; Hoopmann
et al., 2015, 2016; Keller et al., 2019b; Kolbowski et al., 2018;
Riffle et al., 2016, among a subset of examples). Tools increase
in value through integration; for example, node-link diagrams
that classically display protein interaction data (Combe et al.,
2015) can be supplemented by a display of the residue-level
spectral interpretations (Graham et al., 2019; Riffle et al.,
2016). Visualization tools should be further developed to allow
a seamless interrogation of Cross-linking MS data from a wide
angle of perspectives, with a focus on understanding the data
and developing testable hypotheses. This requires linking the
visualization to the public repository of Cross-linking MS data
on one side and public repositories of protein function and inter-
action data on the other side. Visualization tools should have low
entry barriers, such as being browser based (Combe et al., 2015;
Deutsch et al., 2015; Graham et al., 2019; Kolbowski et al., 2018;
Riffle et al., 2016; Trnka et al., 2014) or easy to install (Kosinski
et al., 2015), and be open source and grant funded to ensure
transparent development and access by the widest possible
number of researchers.
Future Development of Cross-linking MS
Recommendation 9: Cross-linking MS Comes in Many
Flavors
Cross-linking MS is currently seeing the rapid prototyping of
novel workflows. These workflows implement different ideas
around the same basic concept but use in part very different
analytical tools. Given the diversity of approaches that exist for
proteomics, it is unclear if a unified workflow will arise for
Cross-linking MS (Leitner et al., 2016; O’Reilly and Rappsilber,
2018; Sinz, 2018; Steigenberger et al., 2020; Yu and Huang,
2018). Therefore, many fundamental elements of the workflow
should not be subject to strict standardization at this point.
This specifically includes (1) cross-linking reagents, as many
types of cross-linking reagents and chemistries exist and new
ones are introduced on a regular basis; (2) instrumentation, as
many types of mass spectrometers with diverse features (e.g.,
fragmentation techniques, real-time decision-making pro-
cesses) exist and certainly the technologywill continue to evolve;
and (3) data analysis software, as many types of cross-linking
analysis software exist and, again, there is a continual develop-
ment of entirely new software tools or new versions of exist-
ing tools.1266 Structure 28, November 3, 2020In addition, there are many different ways of combining chem-
istry, MS, and bioinformatics, although dependencies can and
do exist (e.g., a software will work only with cross-linking re-
agents of a certain design, or it may accept only certain types
of MS data). Although some workflows may be more suitable
than others for a given application, cross-linking can be applied
inmany different contexts. There are a large number of strategies
being explored and that will continue being explored for the fore-
seeable future. Note that diversity also exists in other fields; for
example, many different software tools are used successfully
for protein identification in proteomics.
Recommendation 10: Community Benchmark Exercise
The first community-wide, comparative Cross-linking MS study
published in 2019 (Iacobucci et al., 2019) highlighted the desire
of the field for transparent assessments of the many different
workflows through organized challenges. This should be
continued and expanded to include all application areas of
Cross-linking MS, from single proteins to multi-protein com-
plexes and to highly complex mixtures of proteins. These chal-
lenges should provide both experimentalists and computational
scientists the opportunity to showcase and benchmark their
tools and demonstrate the progress of the field and/or highlight
remaining challenges in the respective areas.
Recommendation 11: Minimal Standards for the
Reporting of New Tools
New cross-linking reagents and new search software (versions)
are frequently reported. Although these reports typically contain
proof-of-principle evidence, they often lack data that allow as-
sessing in full the merits of these new or changed tools. This
not only limits the uptake of these tools but also makes it more
difficult for others to plan experiments in light of the many
choices that are available. We should therefore develop guide-
lines and possibly benchmark challenges that provide the field
with a general comparability of tools and ideally a quantitative
assessment of progress. The above-mentioned organized chal-
lenges are one approach to this, although infrequent and should
be supplemented by rolling and/or fixed challenges. Rolling chal-
lenges are known, for example, in protein structure modeling:
CAMEO (continuous automated model evaluation) (Haas et al.,
2018). Here an available yet confidential structure is used as a
ground truth against which submitted models are assessed.
Especially when it comes to protein-protein interactions, such
a ground truth typically does not exist for Cross-linking MS,
and therefore alternative approaches for evaluation will need to
be developed.
IMPLEMENTATION
Crowd sourcing community standards is known to be a very
time-consuming process. To streamline this process, we sug-
gest that initially a small group gathered from the authors of
this paper and any other interested party (please contact A.L.
or J.R.) proposes such standards. Initial discussionsmay be per-
formed through online discussion groups, where different opin-
ions on best practices can be shared and specific challenges
discussed. Once a consensus emerges, recommendations
would be presented at a community meeting, such as the annual
Symposium on Structural Proteomics, and reported in a
publication. This process is to some extent reminiscent of the
ll
Meeting Reportprocedures established by the HUPO-PSI. Many of the different
aspects of standardization will require significant funding, for
example, to develop new and adapt existing software, and
continuous funding support to ensure that standards and their
implementation tools evolve with the changing needs of this
rapidly developing field. This white paper establishes the foun-
dation of future activities by defining common goals of the
Cross-linking MS community. This is an essential first step to
show funding bodies that this is not an isolated effort of a single
or a few research groups.
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